Evidence map›Paper›PMID 20001422›Full record

ReviewAutoimmunity2010

The biology of reactive intermediates in systemic lupus erythematosus.

Jim C Oates

Open access · greenAbstract readReview
In one paragraph

Review in Autoimmunity, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 51 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Understanding mechanisms of hypertension in systemic lupus erythematosus.Therapeutic advances in cardiovascular disease · 2016
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. HSP90 inhibition by 17-DMAG reduces inflammation in J774 macrophages through suppression of Akt and nuclear factor-κB pathways.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2012
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Jim C OatesMedical Service, Ralph H. Johnson VA Medical Center, Charleston, SC 29425, USA. oatesjc@musc.edu
Ralph H. Johnson VA Medical Center · US

Funding

ZINC AND COPPER METABOLISM IN COLLAGEN DISORDERSM01RR001070 · NCRR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI REVES, JOSEPH G · 1985 to 2009
$16.3M
Role of reactive intermediates in lupus nephritisR01AR045476 · NIAMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI GILKESON, GARY S, OATES, JAMES C · 1999 to 2012
$3.5M
NCRR NIH HHS M01 RR001070NCRR NIH HHS M01RR001070NIAMS NIH HHS AR045476NIAMS NIH HHS R01 AR045476
6 · The paper itself

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune syndrome marked by autoantibody production. Innate immunity is essential to transform humoral autoimmunity into the clinical lupus phenotype. Nitric oxide (NO) is a membrane- permeable signaling molecule involved in a broad array of biologic processes through its ability to modify proteins, lipids, and DNA and alter their function and immunogenicity. The literature regarding mechanisms through which NO regulates inflammation and cell survival is filled with contradictory findings. However, the effects of NO on cellular processes depend on its concentration and its interaction with reactive oxygen. Understanding this interaction will be essential to determine mechanisms through which reactive intermediates induce cellular autoimmunity and contribute to a sustained innate immune response and organ damage in SLE.

Indexed as

AutoantibodiesHumansImmunity, InnateLupus Erythematosus, SystemicReactive Nitrogen SpeciesReactive Oxygen SpeciesAutoantibodiesReactive Nitrogen SpeciesReactive Oxygen Species

Identifiers

PMID20001422
PMCPMC2857664
OpenAlexW2126392124

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.